NO20052136L - Vaksine mot Hepatitt C-virus (HCV). - Google Patents

Vaksine mot Hepatitt C-virus (HCV).

Info

Publication number
NO20052136L
NO20052136L NO20052136A NO20052136A NO20052136L NO 20052136 L NO20052136 L NO 20052136L NO 20052136 A NO20052136 A NO 20052136A NO 20052136 A NO20052136 A NO 20052136A NO 20052136 L NO20052136 L NO 20052136L
Authority
NO
Norway
Prior art keywords
hcv
hepatitis
virus
present
vaccine
Prior art date
Application number
NO20052136A
Other languages
English (en)
Other versions
NO20052136D0 (no
Inventor
Paul A Hamblin
Sara Brett
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20052136D0 publication Critical patent/NO20052136D0/no
Publication of NO20052136L publication Critical patent/NO20052136L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse angår metoder og preparater anvendelige i behandling og forebygging av hepatitt C-virus (HCV) infeksjoner og symptomer og sykdommer assosiert dermed. Spesielt angår foreliggende oppfinnelse DNA-vaksiner omfattende polynukleotidsekvenser som koder for HCV-proteiner og metoder for behandling av individer infisert med HCV omfattende administrering av vaksinene ifølge foreliggende oppfinnelse.
NO20052136A 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV). NO20052136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012830 WO2004046176A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv

Publications (2)

Publication Number Publication Date
NO20052136D0 NO20052136D0 (no) 2005-05-02
NO20052136L true NO20052136L (no) 2005-07-11

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.

Country Status (21)

Country Link
US (4) US20060135451A1 (no)
EP (2) EP1560844A1 (no)
JP (2) JP2006518331A (no)
KR (2) KR20050085010A (no)
CN (2) CN1738833A (no)
AR (1) AR041964A1 (no)
AU (2) AU2003288084A1 (no)
BR (2) BR0316244A (no)
CA (2) CA2504654A1 (no)
CO (1) CO5700833A2 (no)
GB (1) GB0226722D0 (no)
IS (2) IS7830A (no)
MA (2) MA27700A1 (no)
MX (2) MXPA05005202A (no)
NO (2) NO20052149L (no)
NZ (2) NZ539998A (no)
PL (2) PL376882A1 (no)
RU (2) RU2363492C2 (no)
TW (1) TW200502246A (no)
WO (2) WO2004046175A1 (no)
ZA (2) ZA200503802B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
CA2645177A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
AU2009273949A1 (en) * 2008-07-24 2010-01-28 Aduro Biotech Compositions and methods for the treatment of hepatitis C
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
AU2014221143B2 (en) * 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0789563B8 (en) * 1994-10-05 2004-11-17 Apollon, Inc. Hepatitis virus b and c vaccines
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
EP1232267B1 (en) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2363492C2 (ru) 2009-08-10
US20060246090A1 (en) 2006-11-02
MXPA05005203A (es) 2006-01-27
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
CN1738833A (zh) 2006-02-22
EP1560845A1 (en) 2005-08-10
CA2504715A1 (en) 2004-06-03
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
GB0226722D0 (en) 2002-12-24
WO2004046176A1 (en) 2004-06-03
AU2003288084A1 (en) 2004-06-15
NO20052149D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
CN1738834A (zh) 2006-02-22
EP1560844A1 (en) 2005-08-10
KR20050085009A (ko) 2005-08-29
MXPA05005202A (es) 2006-01-27
BR0316291A (pt) 2005-10-11
KR20050085010A (ko) 2005-08-29
NZ539999A (en) 2008-03-28
JP2006518331A (ja) 2006-08-10
MA27699A1 (fr) 2006-01-02
CO5700833A2 (es) 2006-11-30
CA2504654A1 (en) 2004-06-03
PL376967A1 (pl) 2006-01-23
US20090232847A1 (en) 2009-09-17
NZ539998A (en) 2008-04-30
RU2005113692A (ru) 2006-01-27
MA27700A1 (fr) 2006-01-02
AR041964A1 (es) 2005-06-01
ZA200503802B (en) 2006-08-30
PL376882A1 (pl) 2006-01-09
TW200502246A (en) 2005-01-16
AU2003288072A1 (en) 2004-06-15
IS7830A (is) 2005-04-28
IS7831A (is) 2005-04-28
WO2004046175A1 (en) 2004-06-03
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
NO20052149L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
EA200700243A1 (ru) Способы лечения гепатита с
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
IS7533A (is) Lifrarbólgu C-veirutálmar
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
EA200900298A1 (ru) Ингибиторы вируса гепатита с
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
RU2010153688A (ru) Режим дозирования телапревира
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
TW200509964A (en) VP1 of foot-and-mouth disease virus
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
NO20053189L (no) HVC-kombinasjonsterapi.
WO2004082596A3 (en) Yersinia species compositions
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application